Skip to main content
OCRXinactive

OCERA THERAPEUTICS, INC.

Biopharma developer (SEC filing verified)·Phase 2·CEO: Redwood City
Gastroenterology

OCRX evidence brief

What we can confirm

BioSniper Score:
4.7 / 10
Lead Asset:
ocr-002 (Phase 2)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 4.7 / 10 · Lead Asset: ocr-002 (Phase 2)
BioSniper AIPage evidence connected

Prepared research question

What matters most for OCRX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

4.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

ocr-002 (Phase 2)

Next Catalyst

—

Tracking 1 pipeline candidate · 1 clinical trial for OCERA THERAPEUTICS, INC..

Run OCERA THERAPEUTICS, INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available OCERA THERAPEUTICS, INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is OCERA THERAPEUTICS, INC.'s lead drug candidate?

OCERA THERAPEUTICS, INC.'s most advanced tracked candidate is ocr-002 (Phase 2) for Hepatic encephalopathy (HE).

Who is the CEO of OCERA THERAPEUTICS, INC.?

Redwood City is the chief executive officer of OCERA THERAPEUTICS, INC. (OCRX).

What therapeutic areas does OCERA THERAPEUTICS, INC. focus on?

OCERA THERAPEUTICS, INC. develops therapies across Gastroenterology.

923 companies304,844 SEC filings22,644 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.